Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
39
IFRX Quote, Financials, Valuation and Earnings
Last price:
$0.87
Seasonality move
:
-0.18%
Day range:
$0.83 - $0.89
52-week range:
$0.71 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
280.79x
P/B ratio:
0.76x
Volume:
72.2K
Avg. volume:
402.2K
1-year change:
-49.4%
Market cap:
$57.6M
Revenue:
$179.4K
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$24.7K | -$0.23 | 256.48% | -10.49% | $3.62 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics
|
$714.3K | -$0.54 | -- | -26.67% | $44.50 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics
|
$2.5M | -$0.95 | -98.11% | -1571.33% | $23.00 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.43 | -- | -42.18% | $39.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$0.85 | $3.62 | $57.6M | -- | $0.00 | 0% | 280.79x |
|
CDT
Conduit Pharmaceuticals
|
$2.19 | -- | $1.7M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics
|
$35.19 | $44.50 | $990.5M | -- | $1.03 | 0% | -- |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics
|
$16.26 | $23.00 | $696.4M | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$14.80 | $39.50 | $554.1M | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-- | 1.115 | -- | 3.85x |
|
CDT
Conduit Pharmaceuticals
|
-- | 1.154 | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | 0.499 | -- | -- |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -0.228 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-$9.8K | -$13.7M | -56.78% | -56.78% | 1207051.66% | -$14.8M |
|
CDT
Conduit Pharmaceuticals
|
-- | -$4M | -- | -- | -- | -$4.3M |
|
LENZ
LENZ Therapeutics
|
-- | -$16.9M | -- | -- | -- | -$16.2M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$25.1M | -- | -- | -- | -$20.9M |
InflaRx NV vs. Competitors
-
Which has Higher Returns IFRX or CDT?
Conduit Pharmaceuticals has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M CDTConduit Pharmaceuticals-- -$19.80 -- -
What do Analysts Say About IFRX or CDT?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 325.65%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Conduit Pharmaceuticals, analysts believe InflaRx NV is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 CDTConduit Pharmaceuticals0 0 0 -
Is IFRX or CDT More Risky?
InflaRx NV has a beta of 1.291, which suggesting that the stock is 29.054% more volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or CDT?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or CDT?
InflaRx NV quarterly revenues are -$450, which are larger than Conduit Pharmaceuticals quarterly revenues of --. InflaRx NV's net income of -$8.7M is lower than Conduit Pharmaceuticals's net income of -$5.1M. Notably, InflaRx NV's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 280.79x versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV280.79x -- -$450 -$8.7M CDTConduit Pharmaceuticals-- -- -- -$5.1M
-
Which has Higher Returns IFRX or LENZ?
LENZ Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M LENZLENZ Therapeutics-- -$0.53 -- -
What do Analysts Say About IFRX or LENZ?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 325.65%. On the other hand LENZ Therapeutics has an analysts' consensus of $44.50 which suggests that it could grow by 26.46%. Given that InflaRx NV has higher upside potential than LENZ Therapeutics, analysts believe InflaRx NV is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 LENZLENZ Therapeutics5 0 0 -
Is IFRX or LENZ More Risky?
InflaRx NV has a beta of 1.291, which suggesting that the stock is 29.054% more volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LENZ?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. InflaRx NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LENZ?
InflaRx NV quarterly revenues are -$450, which are larger than LENZ Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than LENZ Therapeutics's net income of -$14.6M. Notably, InflaRx NV's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 280.79x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV280.79x -- -$450 -$8.7M LENZLENZ Therapeutics-- -- -- -$14.6M
-
Which has Higher Returns IFRX or LIMN?
Liminatus Pharma has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About IFRX or LIMN?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 325.65%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Liminatus Pharma, analysts believe InflaRx NV is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 LIMNLiminatus Pharma0 0 0 -
Is IFRX or LIMN More Risky?
InflaRx NV has a beta of 1.291, which suggesting that the stock is 29.054% more volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LIMN?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LIMN?
InflaRx NV quarterly revenues are -$450, which are larger than Liminatus Pharma quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Liminatus Pharma's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 280.79x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV280.79x -- -$450 -$8.7M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns IFRX or MAZE?
Maze Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Maze Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M MAZEMaze Therapeutics-- -- -- -
What do Analysts Say About IFRX or MAZE?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 325.65%. On the other hand Maze Therapeutics has an analysts' consensus of $23.00 which suggests that it could grow by 41.45%. Given that InflaRx NV has higher upside potential than Maze Therapeutics, analysts believe InflaRx NV is more attractive than Maze Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 MAZEMaze Therapeutics4 0 0 -
Is IFRX or MAZE More Risky?
InflaRx NV has a beta of 1.291, which suggesting that the stock is 29.054% more volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or MAZE?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or MAZE?
InflaRx NV quarterly revenues are -$450, which are larger than Maze Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Maze Therapeutics's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 280.79x versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV280.79x -- -$450 -$8.7M MAZEMaze Therapeutics-- -- -- --
-
Which has Higher Returns IFRX or ORKA?
Oruka Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M ORKAOruka Therapeutics-- -$0.40 -- -
What do Analysts Say About IFRX or ORKA?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 325.65%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 166.89%. Given that InflaRx NV has higher upside potential than Oruka Therapeutics, analysts believe InflaRx NV is more attractive than Oruka Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 ORKAOruka Therapeutics7 0 0 -
Is IFRX or ORKA More Risky?
InflaRx NV has a beta of 1.291, which suggesting that the stock is 29.054% more volatile than S&P 500. In comparison Oruka Therapeutics has a beta of -0.343, suggesting its less volatile than the S&P 500 by 134.274%.
-
Which is a Better Dividend Stock IFRX or ORKA?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. InflaRx NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or ORKA?
InflaRx NV quarterly revenues are -$450, which are larger than Oruka Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Oruka Therapeutics's net income of -$21M. Notably, InflaRx NV's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 280.79x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV280.79x -- -$450 -$8.7M ORKAOruka Therapeutics-- -- -- -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
